Loading...
Docoh

Abbott Laboratories (ABT)

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Company profile

Ticker
ABT
Exchange
Website
CEO
Robert Ford
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Abbott Biologicals, LLC • Abbott Cardiovascular Inc. • Abbott Cardiovascular Systems Inc. • Abbott Delaware LLC • Abbott Diabetes Care Inc. • Abbott Diabetes Care Sales Corporation • Abbott Diagnostics Scarborough, Inc. • Abbott Equity Investments LLC • Abbott Finance LLC • Abbott Global LLC ...
IRS number
360698440

ABT stock data

Press releases

From Benzinga Pro
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT
1 Oct 22
New York, New York--(Newsfile Corp. - October 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE:ABT) between February 19, 2021 and June
ABBOTT LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT
30 Sep 22
NEW ORLEANS, Sept. 30, 2022 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 31, 2022
ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline
30 Sep 22
New York, New York--(Newsfile Corp. - September 30, 2022) - Levi & Korsinsky, LLP notifies investors in Abbott Laboratories ("Abbott" or the "Company") (NYSE:ABT) of a class action securities lawsuit.The lawsuit on
ABT LOSS ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT
30 Sep 22
CLASS ACTION UPDATE for HGEN, ABT and FLGT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
30 Sep 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

2 Aug 22
1 Oct 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
8 Sep 22 Joseph J Manning Common shares without par value Sell Dispose S No No 107 23,008 2.46M 53,245
8 Sep 22 Joseph J Manning Common shares without par value Option exercise Acquire M No No 44.4 23,008 1.02M 76,253
8 Sep 22 Joseph J Manning Option Common Shares Option exercise Dispose M No No 44.4 23,008 1.02M 0
25 Aug 22 Joseph J Manning Common shares without par value Sell Dispose S No No 105.24 3,890 409.38K 53,245
25 Aug 22 Joseph J Manning Common shares without par value Sell Dispose S No No 104.9941 23,008 2.42M 57,135
25 Aug 22 Joseph J Manning Common shares without par value Option exercise Acquire M No No 44.4 23,008 1.02M 80,143
25 Aug 22 Joseph J Manning Option Common Shares Option exercise Dispose M No No 44.4 23,008 1.02M 23,008
25 Aug 22 Robert B Ford Common shares without par value Sell Dispose S No No 105.1028 102,425 10.77M 142,071
25 Aug 22 Robert B Ford Common shares without par value Option exercise Acquire M No No 41.14 56,933 2.34M 244,496
25 Aug 22 Robert B Ford Common shares without par value Option exercise Acquire M No No 39.12 45,492 1.78M 187,563
72.4% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 2606 2672 -2.5%
Opened positions 97 147 -34.0%
Closed positions 163 204 -20.1%
Increased positions 1026 1063 -3.5%
Reduced positions 1074 1044 +2.9%
13F shares Current Prev Q Change
Total value 160.29B 173.66B -7.7%
Total shares 1.27B 1.27B +0.1%
Total puts 4.42M 6.23M -29.1%
Total calls 6.25M 7.81M -19.9%
Total put/call ratio 0.7 0.8 -11.4%
Largest owners Shares Value Change
Vanguard 152.55M $16.57B +0.8%
BLK Blackrock 135.41M $14.71B +1.9%
Capital Research Global Investors 80.1M $8.7B -0.7%
STT State Street 73.79M $8.02B +0.1%
Capital International Investors 50.52M $5.49B +0.5%
MS Morgan Stanley 36.44M $3.96B +22.0%
Geode Capital Management 29.41M $3.19B +3.0%
Massachusetts Financial Services 25.46M $2.77B -1.6%
BAC Bank Of America 24.33M $2.64B +0.1%
NTRS Northern Trust 24.3M $2.64B -4.2%
Largest transactions Shares Bought/sold Change
Polen Capital Management 15.37M -7.05M -31.4%
Parametric Portfolio Associates 0 -6.74M EXIT
MS Morgan Stanley 36.44M +6.56M +22.0%
Jennison Associates 10.93M +4.87M +80.5%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 5.34M +4.4M +468.2%
BLK Blackrock 135.41M +2.55M +1.9%
Putnam Investments 3.44M +2.35M +215.4%
CFS Investment Advisory Services 18.61K -2.2M -99.2%
Vanguard 152.55M +1.26M +0.8%
Renaissance Technologies 4.22M +1.08M +34.2%

Financial report summary

?
Management Discussion
  • The increase in Total Net Sales in 2021 reflects volume growth across all of Abbott’s segments. In 2021, Abbott’s COVID-19 testing-related sales totaled approximately $7.7 billion led by combined sales of approximately $6.6 billion related to Abbott’s BinaxNOW, Panbio, and ID NOW rapid testing platforms. In 2021, excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased 15.2 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales in 2021 increased 13.7 percent. The price decline related to the Diagnostic Products segment in 2021 primarily reflects lower pricing for COVID-19 tests. The increase in Total Net Sales in 2020 reflects volume growth in the Diagnostics and Nutritional Products segments. In 2020, COVID-19 testing-related sales totaled approximately $3.9 billion. In Medical Devices, the 2020 impact of COVID-19 on Abbott’s cardiovascular and neuromodulation businesses was partially offset by double-digit volume growth in Diabetes Care. The price declines related to the Medical Devices segment in 2021 and 2020 primarily reflect DES pricing pressures as a result of market competition in the U.S. and other major markets.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accuracy, Arizona, automatically, Casa, chain, consent, conversion, decree, digit, double, EleCare, Grande, Ireland, metabolic, Michigan, mitigate, Ohio, plant, prioritization, quarantine, resume, shipment, smallest, staffing, supply, thinnest, wearable
Removed: combined, Evaluation, October